ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Santanello, N.
Right arrow Articles by Zhang, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Santanello, N.
Right arrow Articles by Zhang, J
Eur Respir J 1997; 10: 646-651
Copyright © ERS Journals Ltd 1997


Original Articles

Measurement characteristics of two asthma symptom diary scales for use in clinical trials

NC Santanello, BL Barber, TF Reiss, BS Friedman, EF Juniper, and J Zhang

The measurement characteristics of two asthma symptom diary scales developed for use as health outcome measures in clinical trials of asthma therapy were investigated. A daytime diary scale was designed to capture the frequency and inconvenience of daytime asthma symptoms and their effects on activities, and a nocturnal asthma symptom diary scale was designed to capture awakenings with asthma symptoms. The internal consistency, reliability, validity and responsiveness of both asthma diary scales were assessed in 346 adult asthma patients in two placebo-controlled clinical trials of an investigational asthma therapy, a leukotriene biosynthesis inhibitor. The daytime symptom scale showed sufficient internal consistency (0.90-0.92), and the daytime and nocturnal symptom scales showed sufficient test retest reliability (0.69-0.87). Construct validity was demonstrated by generally moderate-to-strong correlations for changes in the diary scales with changes in other measures of asthma status, such as forced expiratory volume in one second (FEV1), peak expiratory flow (PEF), and puffs of beta-agonist inhaler. Both scales demonstrated significant responsiveness to change in asthma due to therapy in one of the clinical trials. Based on these results, the daytime and nocturnal asthma symptom diary scales show measurement characteristics appropriate for use as asthma outcome measures in clinical trials of asthma therapy.


This article has been cited by other articles:


Home page
ThoraxHome page
E J Hothersall, R Chaudhuri, C McSharry, I Donnelly, J Lafferty, A D McMahon, C J Weir, J Meiklejohn, N Sattar, I McInnes, et al.
Effects of atorvastatin added to inhaled corticosteroids on lung function and sputum cell counts in atopic asthma
Thorax, December 1, 2008; 63(12): 1070 - 1075.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
W. W. Busse, E. Israel, H. S. Nelson, J. W. Baker, B. L. Charous, D. Y. Young, V. Vexler, R. S. Shames, and the Daclizumab Asthma Study Group
Daclizumab Improves Asthma Control in Patients with Moderate to Severe Persistent Asthma: A Randomized, Controlled Trial
Am. J. Respir. Crit. Care Med., November 15, 2008; 178(10): 1002 - 1008.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
E. Livingston, R. Chaudhuri, A. D. McMahon, I. Fraser, C. P. McSharry, and N. C. Thomson
Systemic sensitivity to corticosteroids in smokers with asthma
Eur. Respir. J., January 1, 2007; 29(1): 64 - 71.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
R. Chaudhuri, E. Livingston, A. D. McMahon, J. Lafferty, I. Fraser, M. Spears, C. P. McSharry, and N. C. Thomson
Effects of Smoking Cessation on Lung Function and Airway Inflammation in Smokers with Asthma
Am. J. Respir. Crit. Care Med., July 15, 2006; 174(2): 127 - 133.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
S. L. Johnston, F. Blasi, P. N. Black, R. J. Martin, D. J. Farrell, R. B. Nieman, and the TELICAST Investigators
The Effect of Telithromycin in Acute Exacerbations of Asthma
N. Engl. J. Med., April 13, 2006; 354(15): 1589 - 1600.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
D. Peters, C. Chen, L. E. Markson, F. C. Allen-Ramey, and W. M. Vollmer
Using an asthma control questionnaire and administrative data to predict health-care utilization.
Chest, April 1, 2006; 129(4): 918 - 924.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
E.F. Juniper, M.E. Wisniewski, F.M. Cox, A.H. Emmett, K.E. Nielsen, and P.M. O'Byrne
Relationship between quality of life and clinical status in asthma: a factor analysis
Eur. Respir. J., February 1, 2004; 23(2): 287 - 291.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
R. Chaudhuri, E. Livingston, A. D. McMahon, L. Thomson, W. Borland, and N. C. Thomson
Cigarette Smoking Impairs the Therapeutic Response to Oral Corticosteroids in Chronic Asthma
Am. J. Respir. Crit. Care Med., December 1, 2003; 168(11): 1308 - 1311.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
M J Vaquerizo, P Casan, J Castillo, M Perpina, J Sanchis, V Sobradillo, A Valencia, H Verea, J L Viejo, C Villasante, et al.
Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma
Thorax, March 1, 2003; 58(3): 204 - 210.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
D B Price, D Hernandez, P Magyar, J Fiterman, K M Beeh, I G James, S Konstantopoulos, R Rojas, J A van Noord, M Pons, et al.
Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma
Thorax, March 1, 2003; 58(3): 211 - 216.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
R.A. Baumgartner, G. Martinez, J.M. Edelman, G.G. Rodriguez Gomez, M. Bernstein, S. Bird, R. Angner, A. Polis, S.B. Dass, S. Lu, et al.
Distribution of therapeutic response in asthma control between oral montelukast and inhaled beclomethasone
Eur. Respir. J., January 1, 2003; 21(1): 123 - 128.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
J. Zhang, C. Yu, S.T. Holgate, and T.F. Reiss
Variability and lack of predictive ability of asthma end-points in clinical trials
Eur. Respir. J., November 1, 2002; 20(5): 1102 - 1109.
[Abstract] [Full Text] [PDF]


Home page
Arch. Dis. Child.Home page
A B Chang, V A Harrhy, J Simpson, I B Masters, and P G Gibson
Cough, airway inflammation, and mild asthma exacerbation
Arch. Dis. Child., April 1, 2002; 86(4): 270 - 275.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
W. M. VOLLMER, L. E. MARKSON, E. O'CONNOR, E. ANN FRAZIER, M. BERGER, and A. S. BUIST
Association of Asthma Control with Health Care Utilization . A Prospective Evaluation
Am. J. Respir. Crit. Care Med., January 15, 2002; 165(2): 195 - 199.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
S.-E. DAHLEN, K. MALMSTROM, E. NIZANKOWSKA, B. DAHLEN, P. KUNA, M. KOWALSKI, W. R. LUMRY, C. PICADO, D. D. STEVENSON, J. BOUSQUET, et al.
Improvement of Aspirin-Intolerant Asthma by Montelukast, a Leukotriene Antagonist . A Randomized, Double-Blind, Placebo-Controlled Trial
Am. J. Respir. Crit. Care Med., January 1, 2002; 165(1): 9 - 14.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
S. Shingo, J. Zhang, and T.F. Reiss
Correlation of airway obstruction and patient-reported endpoints in clinical studies
Eur. Respir. J., February 1, 2001; 17(2): 220 - 224.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
A. Reicin, R. White, S. F. Weinstein, A. F. Finn Jr, H. Nguyen, I. Peszek, L. Geissler, B. C. Seidenberg, and for the Montelukast/Loratadine Study Group
Montelukast, a Leukotriene Receptor Antagonist, in Combination With Loratadine, a Histamine Receptor Antagonist, in the Treatment of Chronic Asthma
Arch Intern Med, September 11, 2000; 160(16): 2481 - 2488.
[Abstract] [Full Text]


Home page
Arch Fam MedHome page
A. G. Mainous III, W. J. Hueston, and M. K. Connor
Serum Vitamin C Levels and Use of Health Care Resources for Wheezing Episodes
Arch Fam Med, March 1, 2000; 9(3): 241 - 245.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
M. LAVIOLETTE, K. MALMSTROM, S. LU, P. CHERVINSKY, J.-C. PUJET, I. PESZEK, J. ZHANG, and T. F. REISS
Montelukast Added to Inhaled Beclomethasone in Treatment of Asthma
Am. J. Respir. Crit. Care Med., December 1, 1999; 160(6): 1862 - 1868.
[Abstract] [Full Text]


Home page
BMJHome page
C.-G. Löfdahl, T. F Reiss, J. A Leff, E. Israel, M. J Noonan, A. F Finn, B. C Seidenberg, T. Capizzi, S. Kundu, and P. Godard
Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients
BMJ, July 10, 1999; 319(7202): 87 - 90.
[Abstract] [Full Text]


Home page
Arch. Dis. Child.Home page
N. C Santanello, G. Davies, S. P Galant, A. Pedinoff, R. Sveum, J. Seltzer, B. C Seidenberg, and B. A Knorr
Validation of an asthma symptom diary for interventional studies
Arch. Dis. Child., May 1, 1999; 80(5): 414 - 420.
[Abstract] [Full Text]


Home page
ANN INTERN MEDHome page
K. Malmstrom, G. Rodriguez-Gomez, J. Guerra, C. Villaran, A. Pineiro, L. X. Wei, B. C. Seidenberg, T. F. Reiss, and for the Montelukast/Beclomethasone Study Group*
Oral Montelukast, Inhaled Beclomethasone, and Placebo for Chronic Asthma: A Randomized, Controlled Trial
Ann Intern Med, March 16, 1999; 130(6): 487 - 495.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
T. F. Reiss, P. Chervinsky, R. J. Dockhorn, S. Shingo, B. Seidenberg, T. B. Edwards, and for the Montelukast Clinical Research Study Group
Montelukast, a Once-Daily Leukotriene Receptor Antagonist, in the Treatment of Chronic Asthma: A Multicenter, Randomized, Double-blind Trial
Arch Intern Med, June 8, 1998; 158(11): 1213 - 1220.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the European Respiratory Society.